Clinical Trial Update: Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 trial of anti-TGF monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Malignant Mesothelioma

Drugs mentioned

• GC1008 (fresolimumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Pleural Malignant Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2020-04-10